NCT07543861 A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease
| NCT ID | NCT07543861 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | University of Michigan |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2026-05-15 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 5 participants in total. It began in 2026-05-15 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research is studying the use of a new type of standing desk in a small number of people to learn about the user experience for people with Parkinson's disease. 12 4-hour sessions will be performed to test the primary hypothesis that dynamic standing improves gait function compared to static standing and control sitting. This study has 2 phases. Phase 1 will be an open-label study and Phase 2 will be an in-lab randomized controlled trial pilot study. This is phase 1 of the study.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Parkinson's Disease Exclusion Criteria: * Inability to stand or walk without an assistive device * History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects * Any other history of medical or psychiatric comorbidity, precluding safe participation in the project. * History of symptomatic cardiovascular or pulmonary disease * History of active rheumatic arthritis * History of stroke or other neurologic conditions with significant residual sensorimotor deficits * History of disabling chronic pain syndrome requiring narcotic analgesics * Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) \<24 and significant impairment in activities of daily living) * Venous ulcerative stasis or severe varicosities. * Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.
Contact & Investigator
Chatkaew Pongmala, PhD
PRINCIPAL INVESTIGATOR
University of Michigan
Frequently Asked Questions
Who can join the NCT07543861 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07543861 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07543861 currently recruiting?
Yes, NCT07543861 is actively recruiting participants. Contact the research team at bohnenmi@med.umich.edu for enrollment information.
Where is the NCT07543861 trial being conducted?
This trial is being conducted at Ann Arbor, United States.
Who is sponsoring the NCT07543861 clinical trial?
NCT07543861 is sponsored by University of Michigan. The principal investigator is Chatkaew Pongmala, PhD at University of Michigan. The trial plans to enroll 5 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.